Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Measuring Chemotherapy Completion in Elderly Women

Gynecol Oncol; ePub 2017 Jan 14; von Gruenigen, et al

Elderly patients with ovarian, primary peritoneal, or fallopian tube cancer and with a higher baseline Instrumental Activities of Daily Living (IADL) score were more likely to complete 4 cycles of chemotherapy and less likely to experience grade III or higher toxicity, a recent study found. Patients aged ≥70 years were tested for the ability to complete 4 cycles of first-line chemotherapy without dose reductions or >7 days delay. Patients and their physicians chose between 2 regimens: CP (carboplatin AUC 5, paclitaxel 135 mg/m2), or C (carboplatin AUC 5), both given every 3 weeks either after primary surgery or as neoadjuvant thermotherapy with IADL and quality of life (QOL) assessments performed at baseline, pre-cycle 3, and post-cycle 4. Researchers found:

  • 212 women enrolled (152 selected CP and 60 selected C); those who selected CP had higher baseline IADL scores.
  • Baseline IADL was independently associated with choice of regimen.
  • Baseline IADL score was not associated with completion of 4 cycles of chemotherapy without dose reduction or delays but was associated with completion of 4 cycles regardless of dose reduction and delay and toxicity.
  • IADL was also associated with overall survival for patients receiving CP.

Citation:

von Gruenigen VE, Huang HQ, Beumer JH, et al. Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer – An NRG oncology/Gynecologic Oncology Group study. [Published online ahead of print January 14, 2017]. Gynecol Oncol. doi:10.1016/j.ygyno.2016.11.033.